The clinical potential of prm-PASEF mass spectrometry

被引:12
|
作者
Lesur, Antoine [1 ]
Dittmar, Gunnar [2 ]
机构
[1] Luxembourg Inst Hlth, Proteom Platform, Strassen, Luxembourg
[2] Luxembourg Inst Hlth, Quantitat Biol Unit, Proteom Cellular Signaling Res Grp, Strassen, Luxembourg
关键词
Ion mobility; pasef; targeted proteomics; clinical proteomics; quantification; tims-tof; biomarker; PLASMA PROTEOME;
D O I
10.1080/14789450.2021.1908895
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Introduction The continuous technical improvement in sensitivity and specificity placed mass spectrometry as an alternative method for analyzing clinical samples. In parallel to the rapid development of discovery proteomics, targeted acquisition has been implemented as a complementary option for measuring a small set of proteins with high sensitivity and robustness in a large sample cohort. The combination of trapped ion mobility with a rapid time-of-flight (TOF) mass spectrometer improves the sensitivity even further and triggers the development of prm-PASEF. Areas covered This article discusses the development of prm-PASEF and its advantages over the existing targeted and discovery methods for analyzing clinical samples. We are also highlighting the different requirements for the use of prm-PASEF on clinical samples. Expert opinion prm-PASEF takes advantage of a dual ion-mobility trap enabling highly multiplexed targeted acquisition. It allows the implementation of a short chromatographic separation setup without sacrificing the number of targeted peptides. Analyzing clinical samples by prm-PASEF holds the promise to significantly improve throughput while maintaining sensitivity to detect the selected target proteins.
引用
收藏
页码:75 / 82
页数:8
相关论文
共 50 条
  • [41] Mass spectrometry: a revolution in clinical microbiology?
    Lavigne, Jean-Philippe
    Espinal, Paula
    Dunyach-Remy, Catherine
    Messad, Nourredine
    Pantel, Alix
    Sotto, Albert
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (02) : 257 - 270
  • [42] Empowering Clinical Diagnostics with Mass Spectrometry
    Banerjee, Shibdas
    ACS OMEGA, 2020, 5 (05): : 2041 - 2048
  • [43] Potential of electrospray mass spectrometry for quantifying glycohemoglobin
    Roberts, NB
    Green, BN
    Morris, M
    CLINICAL CHEMISTRY, 1997, 43 (05) : 771 - 778
  • [44] Proof of the quantitative potential of immunofluorescence by mass spectrometry
    Toki, Maria I.
    Cecchi, Fabiola
    Hembrough, Todd
    Syrigos, Konstantinos N.
    Rimm, David L.
    LABORATORY INVESTIGATION, 2017, 97 (03) : 329 - 334
  • [45] Proteomics and cancer diagnosis: the potential of mass spectrometry
    Rodland, KD
    CLINICAL BIOCHEMISTRY, 2004, 37 (07) : 579 - 583
  • [46] Protein biomarker discovery and fast monitoring for the identification and detection of Anisakids by parallel reaction monitoring (PRM) mass spectrometry
    Carrera, Monica
    Gallardo, Jose M.
    Pascual, Santiago
    Gonzalez, Angel F.
    Medina, Isabel
    JOURNAL OF PROTEOMICS, 2016, 142 : 130 - 137
  • [47] The potential of accelerator mass spectrometry in genetic toxicology
    不详
    MUTAGENESIS, 2005, 20 (06) : 476 - 476
  • [48] Recent advances in single-cell MALDI mass spectrometry imaging and potential clinical impact
    Boggio, Kristin J.
    Obasuyi, Emmanuel
    Sugino, Ken
    Nelson, Sacha B.
    Agar, Nathalie Y. R.
    Agar, Jeffrey N.
    EXPERT REVIEW OF PROTEOMICS, 2011, 8 (05) : 591 - 604
  • [49] Mass Spectrometry Analysis for Clinical Applications: A Review
    Zhang, Hong
    Yang, Yali
    Jiang, Yanxiao
    Zhang, Meng
    Xu, Zhilong
    Wang, Xiaofei
    Jiang, Jie
    CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY, 2025, 55 (01) : 213 - 232
  • [50] Proteins and Clinical Mass Spectrometry: A Fairy Tale?
    van den Broek, Irene
    CLINICAL CHEMISTRY, 2019, 65 (02) : 220 - 221